Places are still available on the Factor D Inhibitor Phase 2 C3G Clinical Trial.
Achillion Pharmaceuticals is currently carrying out phase 2 clinical trials of their drug ACH-0144471, a Factor D inhibitor with the aim of treating C3G. Initial results have been positive. Places are available throughout the world including the UK and North America.
UK patients can find out whether they can be part of the trial by contacting Professor Liz Lightstone PhD FRCP at Imperial College London via e-mail at l.lightstone@imperial.ac.uk.
Non UK patients can find trial location information on clinicaltrials.gov. The FDA has approved inclusion of patients aged 12 to 18 in the trial. Achillion can be contacted for more information on 2037525566 or C3GTrialInquiries@achillion.com
For more details including inclusion and exclusion criteria for the trial please follow this link to clinicaltrials.gov https://clinicaltrials.gov/show/NCT03369236